We present here data from a study carried out to assess the efficacy of cefuroxime when given at a dose of 500 mg i.m. three times daily to patients suffering from acute urinary tract infection. We were also concerned to monitor any side-effects and to report on the tolerance of the compound. This open evaluation carried out on patients at Viisterviks Hospital, Sweden included adult patients of both sexes suffering from symptoms associated with infection in the urinary tract and/ or bladder, provided that they had not had at any time an allergic response to a ,-lactam antibiotic, and that they had not had previous chemotherapy for this episode of infection.
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At the start of the study a full clinical evaluation was carried out. Normal routine investigations on both blood and urine were obtained, and a MSU sample was taken for bacteriological culture. Repeat investigations were carried out on samples taken on the third day of treatment, and immediately after stopping treatment.
A dose of 500 mg of cefuroxime sodium was dissolved in 3.5 ml of water for injection and administered 3 times daily by deep i.m. injection into the buttock.
Twenty-nine patients in all are included in this study, 22 of whom were hospitalized for senile dementia. Five patients had heart disease, including one who had chronic cholecystitis. The only concurrent therapy received by these patients was a night sedative, except for one patient who was also receiving digoxin and a further patient having troxerutin.
All the patients were over 60 years of age, 14 were male and 15 female. Table I presents the symptoms of the patients, 27 suffering from an acute episode of chronic cystitis and 2 from acute cystitis. In 22 of the 29 patients the infection was graded as severe, while in the other 7 it was moderate. The mean duration of treatment for patients in this series was 7.3 ±0.5 days.
On the basis of the bacteriological data avail- Table 2 shows the organisms cultured from the MSU samples, with the bacteriological response. In all 29 cases the causative organism was successfully eradicated with this dose of cefuroxime, but in 5 patients there was a superinfection with Pseudomonas aeruginosa, known to be insensitive to cefuroxime. In these elderly patients, Pseudomonas aruginosa was not considered to be pathogenic, for the patients had no symptoms or fever. No specific treatment was given. There was no recurrence of infection in the 24 patients over the 6 week follow-up period.
Clinical assessment was made according to the following criteria:
Success=complete remission of signs and symptoms. Improved=symptoms still present, but showing indications of improvement. Failure=no improvement or patient worse.
Clinical Response
The clinical response is seen in Table 3 which shows that complete remission of symptoms was reported in 28 of the 29 patients at the end of treatment, with I patient still having symptoms but showing signs of improvement. Symptoms of frequency and dysuria have been shown not always to relate to infection of the lower renal tract (Fairley et al. 1971 ). Very often the infection may be within the upper renal tract, either pyelonephritis alone or with an associated bladder infection. Fig 1 gives the day of relief of symptoms for which the patients were admitted to the study and shows that in all the patients relief of the symptoms occurred within the first 4 days, but (as already seen) symptoms persisted to the end of treatment in I case.
Besides the clinical review of the patients, full blood counts and urine analysis, as well as biochemistry for hepatic and renal monitoring, were carried out before treatment, on the 3rd day and at the end of treatment. All 29 patients were assessable in this way but in no instances were any unwanted effects noted, other than those 18- normally seen with patients treated with cephalosporins. One patient had a decrease in hemoglobin and 4 had eosinophilia at the end of therapy although 3 of these patients also had it before treatment.
No overall effects due to cefuroxime were seen in the parameters of hepatic and renal function. None of the transient effects reported were felt to be of significance and would not have been any indication for withdrawing the therapy. No pain was reported from any of the patients in the group on repeated i.m. injection at this dosage and we have no report of other side-effects.
Summary
Twenty-nine patients with troublesome symptoms of cystitis were treated for 1 week with cefuroxime, a new f-lactamase stable cephalosporin derivative. Cefuroxime was administered by deep i.m. injection in a dose of 500 mg three times daily for 7 days. The urine was sterile after 2 days of treatment in all tases and 28 of the 29 patients were symptomless after 3 days. No definite side-effects on the blood, liver or kidneys were observed and the treatment was extremely well tolerated. No allergic or gastrointestinal symptoms were observed and no patient complained of pain at the site of injection.
